Galapagos NV (NASDAQ:GLPG) Analysts Set Average Target Price at $30.75

As of December 22nd, 2024, Galapagos NV (NASDAQ:GLPG) has received an average rating of "Reduce" from seven analysts covering the stock, according to Marketbeat.com. Among these analysts, two have recommended selling the stock, while five have given it a hold recommendation. The consensus 1-year price target for Galapagos by brokerage firms is $30.75.

Several analysts have provided insights on GLPG shares. For instance, Leerink Partners upgraded their recommendation for Galapagos to a “hold” rating in a report dated September 9th. Additionally, the Royal Bank of Canada adjusted their price target for Galapagos from $32.00 to $30.00, maintaining a "sector perform" rating as of November 1st. Further, Leerink Partners initiated coverage of the stock with a “market perform” rating and set a price target of $24.00. Meanwhile, Kepler Capital Markets downgraded Galapagos from a “hold” rating to a “reduce” rating on November 20th.

Institutional Investment Changes

Recent shifts in institutional investment have been notable for Galapagos. AlphaCentric Advisors LLC increased its stake by 3.3% during the second quarter, now holding 108,500 shares valued at approximately $2.69 million after acquiring an additional 3,500 shares. Similarly, Signaturefd LLC increased its holdings by 48.1%, owning 3,872 shares currently worth around $96,000 post a purchase of 1,258 shares. Furthermore, Rhumbline Advisers raised their position in Galapagos by 21.6%, now holding 4,578 shares valued at $113,000 after buying an additional 814 shares during the same period. Monaco Asset Management SAM also boosted its position by 25.4%, holding 20,999 shares valued at $520,000 after acquiring 4,255 additional shares. Lastly, Headlands Technologies LLC increased its stake by 56.7%, adding 446 shares to own a total of 1,233 shares worth $31,000. Overall, approximately 32.46% of Galapagos shares are owned by hedge funds and institutional investors.

Current Trading Status

On Thursday, GLPG stock opened at $26.76. The company's 50-day simple moving average stands at $27.71, while the 200-day simple moving average is at $27.35. Over the past year, Galapagos has experienced a low of $24.16 and a high of $42.46.

Company Overview

Galapagos NV is a biotechnology company focused on developing medicines primarily in oncology and immunology, operating mainly in the United States and Europe. The company's pipeline includes multiple product candidates like GLPG3667, which is in phase 1b trials; GLPG5101, a CD19 CAR-T product also in phase 1/2 trials for relapsed/refractory non-Hodgkin lymphoma; GLPG5201, targeting relapsed/refractory chronic lymphocytic leukemia; and GLPG5301, aimed at relapsed/refractory multiple myeloma.

Galapagos, Analysts, Investment